Drug intelligence / Profile preview

ALF203

Development stage: Preclinical
Lead developer: Beijing Allife Medicine Technology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

ALF203 is an induced pluripotent stem cell (iPSC)-derived cell therapy candidate comprising endothelial progenitor cells (iEPCs). Developed by Allife Medical Science and Technology, ALF203 is specifically designed to address erectile dysfunction resulting from vascular injury. The mechanism of action involves the delivery of iEPCs to the site of injury to facilitate vascular regeneration and endothelial repair. By promoting angiogenesis and restoring the integrity of the penile vasculature, the therapy aims to improve blood flow and restore erectile function. As of the latest pipeline update, ALF203 is in the preclinical stage of development.

Other names: iPSC-derived endothelial progenitor cellsiEPC

Beyond the preview

Go deeper on ALF203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALF203.

Explore the full profile